Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2-positive Breast Cancer × Blood Specimen Collection × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 39 Breast Neoplasms 31 Lung Neoplasms 25 Colorectal Neoplasms 16 Prostatic Neoplasms 14 Pancreatic Neoplasms 11 Ovarian Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Head and Neck Neoplasms 10 Sarcoma 8 Colonic Neoplasms 8 Uterine Cervical Neoplasms 7 Melanoma 7 Glioma 7 Esophageal Neoplasms 7 Carcinoma, Hepatocellular 7 Neoplastic Cells, Circulating 6 Lymphoma 6 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Multiple Myeloma 5 Endometrial Neoplasms 5 Carcinoma, Renal Cell 5 Brain Neoplasms 5 Neoplasm, Residual 4 Gastrointestinal Neoplasms 4 Carcinoma, Squamous Cell 4 Adenocarcinoma 4 Thrombosis 3 Skin Neoplasms 3

Interventions

pyrotinib 6 Trastuzumab 6 pertuzumab 4 Docetaxel 3 Paclitaxel 2 Capecitabine 2 tucatinib 1 trastuzumab deruxtecan 1 neratinib 1 inavolisib 1 Taxoids 1 Neoadjuvant Therapy 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Genetic Testing 1 Drug Therapy 1 Carboplatin 1 Blood Specimen Collection 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04638725 2022-08-03

SIGHER

Institut de cancérologie Strasbourg Europe

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡